PDPN and brain cancer: A combination of IDH1/2 mutation status and podoplanin expression may be helpful in identifying those patients with primary brain cancer who are at high risk of VTE with those having wild type IDH1 and high podoplanin expression having the highest risk and those with mutant IDH1 tumors and absent podoplanin expression having the lowest (18.2% six month risk of VTE versus 0%, respectively) [43].